A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma

被引：0
|
作者：
Apolo, Andrea Borghese
Parnes, Howard L.
Madan, Ravi Amrit
Gulley, James L.
Wright, John Joseph
Khadar, Kattie
Trepel, Jane B.
Schlom, Jeffrey
Arlen, Philip M.
Merino, Maria
Steinberg, Seth M.
Choyke, Peter L.
Lindenberg, Maria Liza
Kurdziel, Karen A.
Folio, Les
Figg, William Douglas
Agarwal, Piyush K.
Bottaro, Donald P.
Dahut, William L.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[3] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] NCI, Rockville, MD USA
[5] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[6] NCI, Lab Tumor Immunol & Biol, Med Oncol Branch, Bethesda, MD 20892 USA
[7] NCI, NIH, Bethesda, MD 20892 USA
[8] NCI, Biostat & Data Management Sect, CCR, Bethesda, MD 20892 USA
[9] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[10] NCI, Mol Imaging Program, CCR, NIH, Bethesda, MD 20892 USA
[11] NIH, Bethesda, MD 20892 USA
[12] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
[13] NCI, Urol Oncol Branchd, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4589
引用
收藏
页数：2
相关论文
共 50 条
  • [1] XL184 (cabozantinib) for medullary thyroid carcinoma
    Durante, Cosimo
    Russo, Diego
    Verrienti, Antonella
    Filetti, Sebastiano
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (03) : 407 - 413
  • [2] A phase I study of cabozantinib (XL184) in patients with renal cell cancer
    Choueiri, T. K.
    Pal, S. K.
    McDermott, D. F.
    Morrissey, S.
    Ferguson, K. C.
    Holland, J.
    Kaelin, W. G.
    Dutcher, J. P.
    ANNALS OF ONCOLOGY, 2014, 25 (08) : 1603 - 1608
  • [3] A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer
    Cabanillas, Maria E.
    Brose, Marcia S.
    Holland, Jaymes
    Ferguson, Kimberly C.
    Sherman, Steven I.
    THYROID, 2014, 24 (10) : 1508 - 1514
  • [4] Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Pal, Sumanta Kumar
    McDermott, David F.
    Ramies, David A.
    Morrissey, Stephanie
    Lee, Yihua
    Miles, Dale
    Holland, Jaymes S.
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [5] Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC)
    Choueiri, Toni K.
    Pal, Sumanta Kumar
    McDermott, David F.
    Ramies, David A.
    Morrissey, Stephanie
    Lee, Yihua
    Miles, Dale
    Holland, Jaymes
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).
    Apolo, Andrea Borghese
    Lee, Young H.
    Cecchi, Fabiola
    Agarwal, Piyush K.
    Parnes, Howard L.
    Khadar, Kattie
    Summerell, Amelia
    Gulley, James L.
    Compton, Kathryn
    Figg, William Douglas
    Dahut, William L.
    Bottaro, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial or the PMH, Chicago, and California Phase II Consortia
    Wilson, Michelle
    Dhani, Neesha C.
    Hirte, Hai W.
    Welch, Stephen
    Steed, Helen
    Martin, Lalnie P.
    Lheureux, Stephanie
    Martin-Lorente, Cristina
    Mackay, Helen
    Butler, Marcus O.
    Wang, Lisa
    Quintos, Judy
    Allen, Katie
    Roman, Lynda
    Wright, John Joseph
    Oza, Amit M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer
    Viola, David
    Cappagli, Virginia
    Elisei, Rossella
    FUTURE ONCOLOGY, 2013, 9 (08) : 1083 - 1092
  • [9] Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC)
    Apolo, Andrea Borghese
    Lee, Young H.
    Cecchi, Fabiola
    Agarwal, Piyush K.
    Parnes, Howard L.
    Khadar, Kattie
    Summerell, Amelia
    Gulley, James L.
    Compton, Kathryn
    Figg, William Douglas
    Dahut, William L.
    Bottaro, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [10] Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT)
    Gordon, Michael S.
    Kluger, Harriet M.
    Shapiro, Geoffrey
    Kurzrock, Razelle
    Edelman, Gerald
    Samuel, Thomas A.
    Moussa, Ali H.
    Ramies, David A.
    Laird, A. Douglas
    Schimmoller, Frauke
    Shen, Xiaodong
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345